ican
Lab Rat
Posts: 28
|
Post by ican on Feb 22, 2017 13:05:18 GMT -5
|
|
|
Post by wgreystone on Feb 22, 2017 13:34:37 GMT -5
MNKD should ask payers what they should do to get Afrezza on the same tier of coverage as Novolog. Lower the drug price 30% or even 50% if have to. To complete against well established treatment options without superior label, insurance coverage is the key. MNKD should have done this 6 months ago.
|
|
|
Post by hans on Feb 22, 2017 13:48:38 GMT -5
|
|
|
Post by surplusvalue on Feb 22, 2017 15:48:44 GMT -5
I dont think MNKD will respond with a price reduction. They have given their reasons for the pricing. Unfortunately MNKD never misses an opportunity to miss an opportunity.
|
|
|
Post by dreamboatcruise on Feb 22, 2017 16:24:53 GMT -5
By and large it is the pharmacy benefit managers and insurers that matter when it comes to pricing. MNKD probably is offering discounts behind the scenes, the way the game is always played.
If I were a PBM/insurer I wouldn't necessarily jump to put AFrezza on a lower tier simply because MNKD made a hoopla about lowering price. In reality PBMs are incentivized to have higher prices. And to the extent the insurer has an incentive to keep prices low, if there isn't something that locks the Afrezza pricing in over the long run, getting a bunch of patients using Afrezza (and creating a monopoly one of a kind superior insulin with no hope of a biosimilar on the horizon) would simply leave MNKD in a position to jack up the price as much or worse than the existing players have done with non-monopoly solutions. Once a lot of patients figure out the benefit of Afrezza they would kick and scream to high heaven if their insurance tried to force them back on SQ prandial.
It is for these reasons I'm actually impressed that MNKD management is making headway with payer coverage... though obviously still a significant way to go.
Caveat... I'm no expert in the business model of drug pricing. It certainly doesn't seem easy to understand or predict winning strategy. I'm primarily pointing out that there are a lot of forces at play.
The discount cards are the common way that pharma, including MNKD, uses to lower prices for the consumer while still maintaining ability to negotiate pricing with the payers.
|
|
|
Post by sayhey24 on Feb 22, 2017 20:44:48 GMT -5
By and large it is the pharmacy benefit managers and insurers that matter when it comes to pricing. MNKD probably is offering discounts behind the scenes, the way the game is always played. If I were a PBM/insurer I wouldn't necessarily jump to put AFrezza on a lower tier simply because MNKD made a hoopla about lowering price. In reality PBMs are incentivized to have higher prices. And to the extent the insurer has an incentive to keep prices low, if there isn't something that locks the Afrezza pricing in over the long run, getting a bunch of patients using Afrezza (and creating a monopoly one of a kind superior insulin with no hope of a biosimilar on the horizon) would simply leave MNKD in a position to jack up the price as much or worse than the existing players have done with non-monopoly solutions. Once a lot of patients figure out the benefit of Afrezza they would kick and scream to high heaven if their insurance tried to force them back on SQ prandial. It is for these reasons I'm actually impressed that MNKD management is making headway with payer coverage... though obviously still a significant way to go. Caveat... I'm no expert in the business model of drug pricing. It certainly doesn't seem easy to understand or predict winning strategy. I'm primarily pointing out that there are a lot of forces at play. The discount cards are the common way that pharma, including MNKD, uses to lower prices for the consumer while still maintaining ability to negotiate pricing with the payers. Interesting idea - "getting a bunch of patients using Afrezza and creating a monopoly". So while MNKD is doing a bunch of stuff like all these studies, they now have these sales guys going door to door. In addition to sales MNKD needs cash and I am thinking they could leverage this new sales team to do both. The fastest way to sales are the current endo's writing scripts and the fastest way to get these endos to write scripts is if they have a vested interest. If MNKD offered a private placement to the endo's, maybe something like a restricted share for 25cents which can't be sold for 3 years or until the pps is $25. If they put a 100,000,000 offering together and sold this to 1000 endos, it would raise $25M and I bet in no time the pps would be $25 and it would be a quick $2.25M for each endo. So, as the sales team introduces afrezza and explains why its the best thing next to a healthy pancreas they could also ask, would you be interested in participating in a private placement. If they are Matt could give them a follow-up call. I thought this may be illegal but after a little research, maybe not.
|
|
|
Post by mango on Feb 22, 2017 21:19:58 GMT -5
“Patients are begging for samples because they can’t afford the insulin,” Levetan said.
“Not asking, you’re saying, begging,” Werner said.
“Begging,” Levetan said.
Like 74-year-old Kathleen Washington. Some months, her insulin runs over $300 a month – more than she can afford.
“I must pay my mortgage,” Washington said.
If it’s a choice between the mortgage and the insulin, “It’s going to be the mortgage,” she said.“Just coincidentally it happens that the three major suppliers of insulin seem to be raising their prices at the same exact time, at the same level. So I think you have to be very naïve not to believe there is collusion,” Sanders said.“If you raise your price, and I raise my price to the same level, what am I saying to you as a company?” Werner asked.“Let’s keep going, or, I’m not going to fight you,” Evans said.The companies deny they’ve broken any laws. Sanofi told CBS News there is “strong competition” on price. Eli Lilly said it is “aggressively competing on net (or negotiated) price,” and Novo Nordisk’s president said on the company’s website that increasing list prices is designed to offset rebates and price concessions to maintain profitability. Lori Reilly, with the trade group that represents U.S. pharmaceutical manufacturers, told CBS News, “I don’t believe there’s been collusion by our companies.” Novo Nordisk responds:Novo Nordisk responds: Many Americans struggle to pay for our medicines and we are focused on working collaboratively toward sustainable solutions. “Under the system that has evolved here in America, the actual price received by a manufacturer is not the list price or the Average Wholesale Price, but rather the net price after very competitive negotiations with a number of middlemen who operate between those of us who make insulin and the patients who use our medicines to control their diabetes.” “We are aware of the complaint and its characterization of the pharmaceutical supply chain. We disagree with the allegations made against the company, and are prepared to vigorously defend the company in this matter. At Novo Nordisk, we have a longstanding commitment to supporting patients’ access to our medicines. Since this is an ongoing litigation, we can’t comment further.” Eli Lilly responds:“Today’s health care system works well for many people, but those enrolled in high-deductible insurance plans and managing chronic conditions face challenges in gaining reasonable access to the treatments they need. Diabetes is one example, and we are committed to doing our part. “Lilly disagrees with the allegations reported to be in the lawsuit. We conduct business in a manner that ensures compliance with all applicable laws, and we adhere to the highest ethical standards.” Sanofi responds:“Sanofi fully understands that the price and affordability of our products is important for patients, and we are committed to helping patients get the treatment they are prescribed. We offer patient assistance programs for patients in need and copay programs for qualified patients whose prescriptions are not paid in part or fully by any state or federally funded program.” “We strongly believe these allegations have no merit, and will defend against these claims. Since this is related to pending litigation, it would be inappropriate to comment further,” said Ashleigh Koss, Sanofi Head of Media Relations, North America. Express Scripts (PBM) responds:“While drug companies have increased the price of insulin, the net costs to payers have been held down. That’s because PBMs like us are doing our job in delivering savings to our clients – the employers, health plans and government entities that pay the most for medicines in this country. Rebates are delivered to those entities and they are used to help bring down benefit premiums and also to ensure a robust pharmacy benefit is provided to workers and families. It is the payers’ decision on how they want to return those rebates to their members. For example, we can, and do at the direction of our clients, provide point of sale rebates directly to a plan member. Most plans would rather receive the rebates and deploy them as they see fit to lower premiums and enhance the benefit. • The main takeaway is this: Rebates don’t raise drug prices, drug makers raise drug prices. Source www.google.com/amp/www.cbsnews.com/amp/news/insulin-price-hike-lawsuit-accuses-drug-makers-of-conspiring/
|
|
|
Post by mango on Feb 22, 2017 22:01:13 GMT -5
• I believe this belongs in here CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2017 EXECUTIVE SUMMARY DISCLOSURESDr. Jeffrey R. Garber reports that he does not have any relevant financial relationships with any commercial interests. Dr. Alan J. Garber reports that he is a consultant for Novo Nordisk and Intarcia Dr. W. Timothy Garvey reports that he is a consultant for AstraZeneca, Janssen, Eisai, Takeda, Novo Nordisk, Alexion, and Merck. He has also received research grants from Merck, Weight Watchers, Sanofi, Eisai, AstraZeneca, Lexicon, Pfizer, Novo Nordisk, and Elcelyx. Dr. Garvey is a shareholder in ISIS Pharmaceuticals, Novartis, Bristol Myers Squibb, Pfizer, Merck, and Eli Lilly. Dr. Martin Julian Abrahamson reports that he is a consultant for Novo Nordisk, WebMD Health Services, and Health IQ. Dr. Joshua I. Barzilay reports that he does not have any relevant financial relationships with any commercial interests. Dr. Lawrence Blonde reports that he is a consultant for AstraZeneca, GlaxoSmithKline, Intarcia, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi. He is also a speaker for AstraZeneca, Janssen Pharmacueticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi. Dr. Blonde has received research grant support from AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi.Dr. George Grunberger reports that he has received speaker honoraria from Eli Lilly, BI-Lilly, Novo Nordisk, Sanofi, Janssen, and AstraZeneca. He has received research funding from AstraZeneca , Eli Lilly, Lexicon, and Medtronic. Dr. Zachary Bloomgarden reports that he is a consultant for AstraZeneca, Johnson & Johnson, Merck, Intarcia, and Novartis. He is also a speaker for Merck, AstraZeneca, and Johnson & Johnson. He is a stock shareholder for Allergan, Pfizer, Zimmer Biomet, and Novartis. Dr. Yehuda Handelsman reports that he is a consultant for Amarin, Amgen, AstraZeneca, Boehringer Ingelheim (BI), Janssen, Eli Lilly, Eisai, Intarcia, Merck, Novo Nordisk, Sanofi, and Regeneron. He is a speaker for Amarin, Amgen, AstraZeneca, BI-Lilly, Janssen, Novo Nordisk, Sanofi, and Regeneron. Dr. Handelsman has also received grant support from Amgen, AstraZeneca, BI, Esperion, Grifols, Hamni, GlaxoSmithKline, Lexicon, Merck, Novo Nordisk, and Sanofi.Dr. Michael A. Bush reports that he is an Advisory Board Consultant for Janssen and Eli Lilly. He is on the speaker’s bureau for Takeda , Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim. Dr. Irl B. Hirsch reports that he is a consultant for Abbott Diabetes Care, Roche, Intarcia, and Valeritas . Dr. Samuel Dagogo-Jack reports that he is a consultant for Merck, Novo Nordisk, Janssen, and Boehringer Ingelheim. He has received research grants from Amgen. Additionally, AstraZeneca, Novo Nordisk, and Boehringer Ingelheim have clinical trial contracts with the University of Tennessee for studies in which Dr. Dagogo-Jack serves as the Principal Investigator or Co-Investigator. Dr. Paul S. Jellinger reports that he has received speaker honoraria from BI-Lilly, AstraZeneca , Novo Nordisk, Merck, and Amgen. Dr. Ralph Anthony DeFronzo reports that he is on the Advisory Board for AstraZeneca, Novo Nordisk, Janssen, Boehringer Ingelheim, Intarcia, and Ecelyx. He is also a speaker for Novo Nordisk and AstraZeneca. Dr. DeFronzo has received research grant support from Boehringer Ingelheim, Takeda, Janssen, and AstraZeneca. Dr. Janet B. McGill reports that she is a consultant for Boehringer Ingelheim, Janssen, Merck, Novo Nordisk, Calibra, Dynavax, Valertias, and Intarcia. She is also a speaker for Janssen. Dr. McGill has received research grant support from Novartis, Dexcom, Bristol Myers Squibb, and Lexicon. Dr. Daniel Einhorn reports that he is a consultant for Eli Lilly, Takeda, Novo Nordisk, Adocia, Sanofi, Epitracker, Janssen, Intarcia, Glysens, and Freedom-Meditech and has received research grant support from Novo Nordisk, Eli Lilly, AstraZeneca, Eisai, Janssen, and Sanofi. He is also a shareholder of Halozyme. Dr. Paul D. Rosenblit reports that he is a consultant for AstraZeneca and a speaker for AstraZeneca (Bristol Myers Squibb), Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, and Takeda. He has also received research grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Ionis, Eli Lilly, Lexicon, Merck, Novo Nordisk, Orexigen, Pfizer, and Sanofi. Dr. Vivian A. Fonseca reports that he is a consultant for Takeda, Novo Nordisk, Sanofi, Eli Lily, Pamlabs, AstraZeneca, Abbott, Boehringer Ingelheim, Janssen and Intarcia. He is a speaker for Takeda, AstraZeneca, and Sanofi. Dr. Fonseca has also received research grants from Novo Nordisk, Asahi , Eli Lilly, Abbott, Endo Barrier, Bayer, and Gilead. Dr. Guillermo E. Umpierrez reports that he is a consultant for Sanofi and Glytec. He also received research grant support from Merck, Sanofi, Boehringer Ingelheim, AstraZeneca, and Novo Nordisk.Dr. Jeffrey I. Mechanick reports that he is a consultant for Abbott Nutrition International. Dr. Stephanie Adams reports that she does not have any relevant financial relationships with any commercial interests. www.aace.com/sites/all/files/diabetes-algorithm-executive-summary.pdf
|
|
|
Post by mango on Feb 22, 2017 22:53:06 GMT -5
• I believe this belongs in here CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2017 EXECUTIVE SUMMARY DISCLOSURESDr. Jeffrey R. Garber reports that he does not have any relevant financial relationships with any commercial interests. Dr. Alan J. Garber reports that he is a consultant for Novo Nordisk and Intarcia Dr. W. Timothy Garvey reports that he is a consultant for AstraZeneca, Janssen, Eisai, Takeda, Novo Nordisk, Alexion, and Merck. He has also received research grants from Merck, Weight Watchers, Sanofi, Eisai, AstraZeneca, Lexicon, Pfizer, Novo Nordisk, and Elcelyx. Dr. Garvey is a shareholder in ISIS Pharmaceuticals, Novartis, Bristol Myers Squibb, Pfizer, Merck, and Eli Lilly. Dr. Martin Julian Abrahamson reports that he is a consultant for Novo Nordisk, WebMD Health Services, and Health IQ. Dr. Joshua I. Barzilay reports that he does not have any relevant financial relationships with any commercial interests. Dr. Lawrence Blonde reports that he is a consultant for AstraZeneca, GlaxoSmithKline, Intarcia, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi. He is also a speaker for AstraZeneca, Janssen Pharmacueticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi. Dr. Blonde has received research grant support from AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi.Dr. George Grunberger reports that he has received speaker honoraria from Eli Lilly, BI-Lilly, Novo Nordisk, Sanofi, Janssen, and AstraZeneca. He has received research funding from AstraZeneca , Eli Lilly, Lexicon, and Medtronic. Dr. Zachary Bloomgarden reports that he is a consultant for AstraZeneca, Johnson & Johnson, Merck, Intarcia, and Novartis. He is also a speaker for Merck, AstraZeneca, and Johnson & Johnson. He is a stock shareholder for Allergan, Pfizer, Zimmer Biomet, and Novartis. Dr. Yehuda Handelsman reports that he is a consultant for Amarin, Amgen, AstraZeneca, Boehringer Ingelheim (BI), Janssen, Eli Lilly, Eisai, Intarcia, Merck, Novo Nordisk, Sanofi, and Regeneron. He is a speaker for Amarin, Amgen, AstraZeneca, BI-Lilly, Janssen, Novo Nordisk, Sanofi, and Regeneron. Dr. Handelsman has also received grant support from Amgen, AstraZeneca, BI, Esperion, Grifols, Hamni, GlaxoSmithKline, Lexicon, Merck, Novo Nordisk, and Sanofi.Dr. Michael A. Bush reports that he is an Advisory Board Consultant for Janssen and Eli Lilly. He is on the speaker’s bureau for Takeda , Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim. Dr. Irl B. Hirsch reports that he is a consultant for Abbott Diabetes Care, Roche, Intarcia, and Valeritas . Dr. Samuel Dagogo-Jack reports that he is a consultant for Merck, Novo Nordisk, Janssen, and Boehringer Ingelheim. He has received research grants from Amgen. Additionally, AstraZeneca, Novo Nordisk, and Boehringer Ingelheim have clinical trial contracts with the University of Tennessee for studies in which Dr. Dagogo-Jack serves as the Principal Investigator or Co-Investigator. Dr. Paul S. Jellinger reports that he has received speaker honoraria from BI-Lilly, AstraZeneca , Novo Nordisk, Merck, and Amgen. Dr. Ralph Anthony DeFronzo reports that he is on the Advisory Board for AstraZeneca, Novo Nordisk, Janssen, Boehringer Ingelheim, Intarcia, and Ecelyx. He is also a speaker for Novo Nordisk and AstraZeneca. Dr. DeFronzo has received research grant support from Boehringer Ingelheim, Takeda, Janssen, and AstraZeneca. Dr. Janet B. McGill reports that she is a consultant for Boehringer Ingelheim, Janssen, Merck, Novo Nordisk, Calibra, Dynavax, Valertias, and Intarcia. She is also a speaker for Janssen. Dr. McGill has received research grant support from Novartis, Dexcom, Bristol Myers Squibb, and Lexicon. Dr. Daniel Einhorn reports that he is a consultant for Eli Lilly, Takeda, Novo Nordisk, Adocia, Sanofi, Epitracker, Janssen, Intarcia, Glysens, and Freedom-Meditech and has received research grant support from Novo Nordisk, Eli Lilly, AstraZeneca, Eisai, Janssen, and Sanofi. He is also a shareholder of Halozyme. Dr. Paul D. Rosenblit reports that he is a consultant for AstraZeneca and a speaker for AstraZeneca (Bristol Myers Squibb), Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, and Takeda. He has also received research grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Ionis, Eli Lilly, Lexicon, Merck, Novo Nordisk, Orexigen, Pfizer, and Sanofi. Dr. Vivian A. Fonseca reports that he is a consultant for Takeda, Novo Nordisk, Sanofi, Eli Lily, Pamlabs, AstraZeneca, Abbott, Boehringer Ingelheim, Janssen and Intarcia. He is a speaker for Takeda, AstraZeneca, and Sanofi. Dr. Fonseca has also received research grants from Novo Nordisk, Asahi , Eli Lilly, Abbott, Endo Barrier, Bayer, and Gilead. Dr. Guillermo E. Umpierrez reports that he is a consultant for Sanofi and Glytec. He also received research grant support from Merck, Sanofi, Boehringer Ingelheim, AstraZeneca, and Novo Nordisk.Dr. Jeffrey I. Mechanick reports that he is a consultant for Abbott Nutrition International. Dr. Stephanie Adams reports that she does not have any relevant financial relationships with any commercial interests. www.aace.com/sites/all/files/diabetes-algorithm-executive-summary.pdfSeems like just about everyone, with the except of a few, on the consensus committee are associated with one of the insulin cartels involved in the alleged insulin price fixing. I am sure it is rather coincidence. 🙄
|
|
|
Post by sayhey24 on Feb 23, 2017 6:29:15 GMT -5
• I believe this belongs in here CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2017 EXECUTIVE SUMMARY DISCLOSURESDr. Jeffrey R. Garber reports that he does not have any relevant financial relationships with any commercial interests. Dr. Alan J. Garber reports that he is a consultant for Novo Nordisk and Intarcia Dr. W. Timothy Garvey reports that he is a consultant for AstraZeneca, Janssen, Eisai, Takeda, Novo Nordisk, Alexion, and Merck. He has also received research grants from Merck, Weight Watchers, Sanofi, Eisai, AstraZeneca, Lexicon, Pfizer, Novo Nordisk, and Elcelyx. Dr. Garvey is a shareholder in ISIS Pharmaceuticals, Novartis, Bristol Myers Squibb, Pfizer, Merck, and Eli Lilly. Dr. Martin Julian Abrahamson reports that he is a consultant for Novo Nordisk, WebMD Health Services, and Health IQ. Dr. Joshua I. Barzilay reports that he does not have any relevant financial relationships with any commercial interests. Dr. Lawrence Blonde reports that he is a consultant for AstraZeneca, GlaxoSmithKline, Intarcia, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi. He is also a speaker for AstraZeneca, Janssen Pharmacueticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi. Dr. Blonde has received research grant support from AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi.Dr. George Grunberger reports that he has received speaker honoraria from Eli Lilly, BI-Lilly, Novo Nordisk, Sanofi, Janssen, and AstraZeneca. He has received research funding from AstraZeneca , Eli Lilly, Lexicon, and Medtronic. Dr. Zachary Bloomgarden reports that he is a consultant for AstraZeneca, Johnson & Johnson, Merck, Intarcia, and Novartis. He is also a speaker for Merck, AstraZeneca, and Johnson & Johnson. He is a stock shareholder for Allergan, Pfizer, Zimmer Biomet, and Novartis. Dr. Yehuda Handelsman reports that he is a consultant for Amarin, Amgen, AstraZeneca, Boehringer Ingelheim (BI), Janssen, Eli Lilly, Eisai, Intarcia, Merck, Novo Nordisk, Sanofi, and Regeneron. He is a speaker for Amarin, Amgen, AstraZeneca, BI-Lilly, Janssen, Novo Nordisk, Sanofi, and Regeneron. Dr. Handelsman has also received grant support from Amgen, AstraZeneca, BI, Esperion, Grifols, Hamni, GlaxoSmithKline, Lexicon, Merck, Novo Nordisk, and Sanofi.Dr. Michael A. Bush reports that he is an Advisory Board Consultant for Janssen and Eli Lilly. He is on the speaker’s bureau for Takeda , Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim. Dr. Irl B. Hirsch reports that he is a consultant for Abbott Diabetes Care, Roche, Intarcia, and Valeritas . Dr. Samuel Dagogo-Jack reports that he is a consultant for Merck, Novo Nordisk, Janssen, and Boehringer Ingelheim. He has received research grants from Amgen. Additionally, AstraZeneca, Novo Nordisk, and Boehringer Ingelheim have clinical trial contracts with the University of Tennessee for studies in which Dr. Dagogo-Jack serves as the Principal Investigator or Co-Investigator. Dr. Paul S. Jellinger reports that he has received speaker honoraria from BI-Lilly, AstraZeneca , Novo Nordisk, Merck, and Amgen. Dr. Ralph Anthony DeFronzo reports that he is on the Advisory Board for AstraZeneca, Novo Nordisk, Janssen, Boehringer Ingelheim, Intarcia, and Ecelyx. He is also a speaker for Novo Nordisk and AstraZeneca. Dr. DeFronzo has received research grant support from Boehringer Ingelheim, Takeda, Janssen, and AstraZeneca. Dr. Janet B. McGill reports that she is a consultant for Boehringer Ingelheim, Janssen, Merck, Novo Nordisk, Calibra, Dynavax, Valertias, and Intarcia. She is also a speaker for Janssen. Dr. McGill has received research grant support from Novartis, Dexcom, Bristol Myers Squibb, and Lexicon. Dr. Daniel Einhorn reports that he is a consultant for Eli Lilly, Takeda, Novo Nordisk, Adocia, Sanofi, Epitracker, Janssen, Intarcia, Glysens, and Freedom-Meditech and has received research grant support from Novo Nordisk, Eli Lilly, AstraZeneca, Eisai, Janssen, and Sanofi. He is also a shareholder of Halozyme. Dr. Paul D. Rosenblit reports that he is a consultant for AstraZeneca and a speaker for AstraZeneca (Bristol Myers Squibb), Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, and Takeda. He has also received research grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Ionis, Eli Lilly, Lexicon, Merck, Novo Nordisk, Orexigen, Pfizer, and Sanofi. Dr. Vivian A. Fonseca reports that he is a consultant for Takeda, Novo Nordisk, Sanofi, Eli Lily, Pamlabs, AstraZeneca, Abbott, Boehringer Ingelheim, Janssen and Intarcia. He is a speaker for Takeda, AstraZeneca, and Sanofi. Dr. Fonseca has also received research grants from Novo Nordisk, Asahi , Eli Lilly, Abbott, Endo Barrier, Bayer, and Gilead. Dr. Guillermo E. Umpierrez reports that he is a consultant for Sanofi and Glytec. He also received research grant support from Merck, Sanofi, Boehringer Ingelheim, AstraZeneca, and Novo Nordisk.Dr. Jeffrey I. Mechanick reports that he is a consultant for Abbott Nutrition International. Dr. Stephanie Adams reports that she does not have any relevant financial relationships with any commercial interests. www.aace.com/sites/all/files/diabetes-algorithm-executive-summary.pdfSeems like just about everyone, with the except of a few, on the consensus committee are associated with one of the insulin cartels involved in the alleged insulin price fixing. I am sure it is rather coincidence. 🙄 They sure are and I suspect they are also stock owners in these companies. I really think MNKD needs to do the same and one way or another make them all owners in MNKD so they all have a vested interest. Another approach instead or in addition to a private Endo placement would be to hire as many as possible and pay them in warrants to give educational speeches on new diabetes approaches which would front and center discuss- afrezza, dexcom and libre and pay them in warrants. That would cost MNKD nothing and would get these guys a piece of the pie.
|
|
|
Post by agedhippie on Feb 23, 2017 9:47:26 GMT -5
Seems like just about everyone, with the except of a few, on the consensus committee are associated with one of the insulin cartels involved in the alleged insulin price fixing. I am sure it is rather coincidence. 🙄 It's not a coincidence at all. If you are an endo doing research you will be getting grants from diabetes drug companies. That doesn't mean they are in anyones pocket, just that a pharma is funding a project. It is also why the disclosures change from year to year - for example in 2015 Dr Irl Hirsch (since you are picking on him) took no money from insulin companies.
|
|
|
Post by matt on Feb 23, 2017 10:45:28 GMT -5
Seems like just about everyone, with the except of a few, on the consensus committee are associated with one of the insulin cartels involved in the alleged insulin price fixing. I am sure it is rather coincidence. 🙄 It's not a coincidence at all. If you are an endo doing research you will be getting grants from diabetes drug companies. That doesn't mean they are in anyones pocket, just that a pharma is funding a project. Exactly correct. I have funded lots of investigators that were working on projects of interest to my companies, but in my experience academics (especially) are in nobody's pocket. I have cringed more than once when an investigator that we had funded generously tactfully suggested to a room full of his colleagues that he would not use our product in particular circumstances. He was right of course, but it was not fun hearing him say it. I am not saying that some people cannot be bought off, but it doesn't happen for the amounts discussed here and in many cases, those funds are tracked and controlled by the hospital or university. Many of the checks are payable to the institution, not the physician directly. The physicians you have to worry about are not those who are disclosing. The ones you need to worry about are those who are getting envelopes full of cash via a quasi-related party (like an "independent" distributor) out in the parking lot after dark. Pay to play is alive and well, but not for those participating in highly public panel discussions.
|
|
|
Post by mango on Feb 23, 2017 12:59:06 GMT -5
Seems like just about everyone, with the except of a few, on the consensus committee are associated with one of the insulin cartels involved in the alleged insulin price fixing. I am sure it is rather coincidence. 🙄 It's not a coincidence at all. If you are an endo doing research you will be getting grants from diabetes drug companies. That doesn't mean they are in anyones pocket, just that a pharma is funding a project. It is also why the disclosures change from year to year - for example in 2015 Dr Irl Hirsch (since you are picking on him) took no money from insulin companies. You missed my sarcasm. And some of these people are not just getting grants, they are stockholders and consultants. They also are the ones that establish recommended guidlelines—which are also in the best interests of the pharmaceutical companies in which they represent. Defend all you want, doesn't change the fact that 3 of them that are being investigated for collusion in insulin price fixing (which was without a doubt deliberately done) are associated with nearly all these individuals.
|
|
|
Post by mango on Feb 23, 2017 15:07:21 GMT -5
Seems like just about everyone, with the except of a few, on the consensus committee are associated with one of the insulin cartels involved in the alleged insulin price fixing. I am sure it is rather coincidence. 🙄 It's not a coincidence at all. If you are an endo doing research you will be getting grants from diabetes drug companies. That doesn't mean they are in anyones pocket, just that a pharma is funding a project. It is also why the disclosures change from year to year - for example in 2015 Dr Irl Hirsch (since you are picking on him) took no money from insulin companies.Could you ever be so far from the truth?! Dr. Irl Hirsch 2015: Total General Payments $22,746.99
Total Associated Research Funding $231,767.05 Pharmaceutical Companies Making Payments: ABBOTT LABORATORIES BECTON, DICKINSON AND COMPANY ROCHE DIABETES CARE GMBH ROCHE DIAGNOSTICS GMBH
openpaymentsdata.cms.gov/physician/311840/summaryopenpaymentsdata.cms.gov/physician/311840/payment-information
|
|
|
Post by mango on Feb 23, 2017 15:13:48 GMT -5
Every one of them have diabetic products, maybe not insulin, but nonetheless, are diabetic affilated.
|
|